metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O-27 IMPACT OF HBV GENOTYPE F IN THE DIAGNOSIS AND EVOLUTION OF PATIENTS WITH HB...
Información de la revista
Vol. 24. Núm. S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(septiembre 2021)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 24. Núm. S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(septiembre 2021)
Open Access
O-27 IMPACT OF HBV GENOTYPE F IN THE DIAGNOSIS AND EVOLUTION OF PATIENTS WITH HBEAG-NEGATIVE CHRONIC HBV INFECTION
Visitas
556
Hugo Fainboim1, Nicolas Dibenedeto2, Paz Silvia1, Mendizabal Manuel3, Soledad Campuzano1, Micaela Martinez4, Luciana Tadey5, Gabriel Deluchi5, Bouzas Belen5, Mammana Lilia5, Diego Flichman4
1 Unidad de Hepatopatías Infecciosas, Hospital de Infecciosas F.J Muñiz, Buenos Aires, Argentina
2 Hospital Arrecifes, Buenos Aires, Argentina
3 Hospital Universitario Austral, Buenos Aires, Argentina
4 Instituto de Investigaciones Biomédicas en Retrovirus y Sida, Buenos Aires, Argentina
5 Unidad de VirologÍa, Hospital de Infecciosas "Francisco J. Muñiz", Buenos Aires, Argentina
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 24. Núm S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

Más datos
Background

The quantitative hepatitis B surface antigen (qHBsAg) threshold of 1,000 IU/ml has been proposed to distinguish HBeAg-negative chronic infections from HBeAg-negative chronic hepatitis, to assess risk of liver disease progression, and to predict HBsAg clearance. There is evidence that qHBsAg vary significantly among genotypes, however, there is scarce data on genotype F, the most prevalent in Latin America.

Aims

To analyze the impact of HBV genotype F on qHBsAg inpatients with HBeAg-negative chronic infection and to describe clinical and virological outcomes.

Methods

HBV-DNA and qHBsAg serum levels of 141 patients with HBeAg-negative chronic infection were correlated with HBV genotype, who were followed for 10.6±7.4 years.

Results

The overall genotype distribution was as follows: F 46.8%, D 26.1%, A 25.2%, and B 0.7% and C 0.7%. While no impact of the HBV genotype on HBV DNA levels was observed, qHBsAg differed significantly among genotypes (p<0.001). The highest HBsAg levels were observed in genotype F (4.0±1.1 Log10IU/ml) followed by genotype A (3.9±0.6 Log10IU/ml) and genotype D (2.4±0.9 Log10IU/ml). In genotype A and F, qHBsAg <3.0 Log10IU/ml were only observed in 10.7% and 11.5% respectively.

Regardless of the HBV genotype, spontaneous clearance of HBsAg was observed in 17 cases. Of these, 12 patients presented qHBsAg <100 IU/ml one year before clearance. Despite, 101 (71.6%) patients showed qHBsAg >3.0 Log10IU/ml, no cases of advanced liver disease or hepatocellular carcinoma were observed at the end of follow-up.

Conclusions

This study provides new insights into the impact of HBV genotypes on serum HBsAg levels, emphasizing the need to implement genotype-specific cut-off to achieve diagnostic certainty in the identification of HBeAg-negative chronic infection and the risk of liver disease progression, particularly on infections with genotypes A and F. Moreover, HBsAg serum levels can became a reliable biomarker to predict HBsAg clearance.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos